Health
Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test – News-Medical.net
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce…
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples.
Avacta is developing several coronavirus tests using Affimer binders that are highly…
-
Business21 hours agoBell Potter names the best ASX tech stocks to buy in FY 2026
-
General17 hours agoHuman remains located, police make arrest in search for Sunbury man Joshua Bishop
-
General15 hours agoNetanyahu denounces report IDF soldiers had orders to shoot Gaza aid-seekers
-
Noosa News24 hours agoHope for regent honeyeater with signs of booming blossoms after NSW rain and floods